PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.440
0.00 (0.00%)
At close: Apr 27, 2026, 4:00 PM EDT
1.440
0.00 (0.00%)
After-hours: Apr 27, 2026, 4:10 PM EDT
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 54 employees as of December 31, 2025. The number of employees increased by 7 or 14.89% compared to the previous year.
Employees
54
Change (1Y)
7
Growth (1Y)
14.89%
Revenue / Employee
n/a
Profits / Employee
-$1,439,667
Market Cap
76.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 54 | 7 | 14.89% |
| Dec 31, 2024 | 47 | -16 | -25.40% |
| Dec 31, 2023 | 63 | 1 | 1.61% |
| Dec 31, 2022 | 62 | 8 | 14.81% |
| Dec 31, 2021 | 54 | 10 | 22.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| ImmuCell | 73 |
| aTyr Pharma | 60 |
| Pliant Therapeutics | 49 |
| Filana Therapeutics | 20 |
| LeonaBio | 19 |
PMVP News
- 5 days ago - PMV Pharmaceuticals Announces Board Chair Transition - GlobeNewsWire
- 7 weeks ago - PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 6 months ago - PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 7 months ago - PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 8 months ago - Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types - Benzinga
- 8 months ago - PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 9 months ago - PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire